Biology meets artificial and human intelligencefor next-generation therapeutics
Agentic Drug Discovery
Our agentic orchestration layer automates model training and experimental feedback across programs, compressing timelines without compromising on quality.
AI-Native Protein Engineering
Our AI models are trained on functional biological outcomes so every optimization cycle moves toward candidates that are more potent, more developable, and more likely to translate.
High-Throughput Functional Assays
From thousands to hundreds of billions of variants per campaign, our proprietary assay platforms generate the scale of data needed for effective training.
Why we are different. Onava is an AI drug discovery platform focused on bispecific antibodies. We design and operate proprietary wet-lab assay platforms that generate large-scale data. We use that data to train AI models that improve with every round.
The drug discovery industry generates enormous amounts of experimental data and throws most of it away. Each program runs in isolation, each experiment is treated as a one-time event, and the insights from failed candidates rarely inform what comes next.
Onava is built differently. Our platform compounds in value with every program we execute. A cross-program data flywheel that means the tenth candidate we optimize benefits from everything learned in the first nine.
Founding Team
Our founding team combines deep expertise in protein engineering, machine learning, and therapeutic development. We have built and scaled wet-lab platforms, trained large biological models, and advanced candidates from discovery through the clinic.
01Ido CalmanCEO & Co-Founder
02Sharrol Bachas, PhDCSO & Co-Founder
03Hamed Alishahi, PhDFounding Scientist
04Puwanat Sangkhapreecha, PhDFounding Scientist
05Zeynep Onder, PhDVP, Operations & Partnerships
Our Mission. We believe the next generation of medicines will be built by platforms that treat every experiment as an input to something larger. Our goal is to build that infrastructure and use it to deliver better biologics, faster, against targets the industry has struggled to address.
